Earnings Summary

Inozyme Pharma Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q4 2023. On a quarterly growth basis, Inozyme Pharma Inc has generated NaN% jump in its revenue since last 3-months.

Inozyme Pharma Inc’s net profit fell -22.72% since last year same period to $-21.54Mn in the Q4 2023. On a quarterly growth basis, Inozyme Pharma Inc has generated -29.49% fall in its net profits since last 3-months.

Inozyme Pharma Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q4 2023. On a quarterly growth basis, Inozyme Pharma Inc has generated NaN% jump in its net profit margins since last 3-months.

Inozyme Pharma Inc’s earning per share (EPS) estimates for the current quarter stand at -0.36 - a -12.5% fall from last quarter’s estimates.

Inozyme Pharma Inc’s earning per share (EPS) estimates for the current year stand at -0.36.

Inozyme Pharma Inc’s earning per share (EPS) jumped 21.43% since last year same period to -0.33 in the Q4 2023. This indicates that the Inozyme Pharma Inc has generated 21.43% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Inozyme Pharma Inc’s return on assets (ROA) stands at -0.28.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Inozyme Pharma Inc’s return on equity (ROE) stands at -0.55.